Cormedics Corporation is a life sciences company focused on developing novel technologies that selectively treat the entire heart with drug, cell, gene, and device therapies by introducing them into the pericardial space.

The Intrapericardial Opportunity
The pericardial sac surrounds and encloses the heart -- it is the ideal location to deliver therapies to the entire heart, from the "outside-in." Traditional drug delivery methods all mix medications with the circulatory system to treat the heart from the "inside-out," but they can also have a toxic effect on other organs. Cormedics has developed a targeted heart therapy to treat just the heart, which has been endorsed by some of the key players in cardiovascular medicine.

Cormedics' Initial Product - PeriPort™

• A minimally invasive device to safely access the "normal" pericardial space.

• Allows drug therapies to be delivered to the coronary vasculature of the heart via the pericardial space.

• Permits fluid to be removed or added interpericardial.

• Device and medication therapies can be delivered, and targeted to the entire heart.

Website: www.cormedicscorp.com